Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sukaina Virji

Sukaina has been reporting on all aspects of the pharmaceutical and biotechnology space since 2000. In her role as News Editor, she is tasked with ensuring Scrip Intelligence continues to provide the business critical information that its subscribers rely on. Sukaina's prior positions include Editor of the newsletter BioVenture View and the magazine BioPeople. She has a PhD in biochemistry and molecular biology from University College London. Based in the UK, Sukaina is often asked to appear on TV and radio to commentate on business and R&D strategy related to the industry.
Advertisement
Set Alert for Articles By Sukaina Virji

Latest From Sukaina Virji

Merck Expands Aduro Collaboration In Keytruda Tie-Up

Aduro Biotech's scientists have a long association with Merck & Co's Keytruda, and things have come full circle as the small biotech's lead anticancer shows promise in combination with the high-profile checkpoint inhibitor.

Research & Development ImmunoOncology

Merck Develops 'New And Improved' CRISPR

Merck of Germany has developed a new genome editing tool that it believes improves on the popular, but IP battle-worn, CRISPR technology. How this will affect the existing IP landscape is as yet unknown.

Research & Development Intellectual Property

Humira's Formulation Patent Loss Boosts Biosimilar Manufacturers

Analysts' views on what the Humira formulation patent loss this week could mean for the launch timing of a biosimilar to AbbVie's main revenue driver vary.

Biosimilars Commercial

Interview With J&J’s CMO Dr Joanne Waldstreicher On Internal And External Challenges To Sharing Clinical Trial Data

"Everything different and worthwhile comes with its challenges," Johnson & Johnson’s chief medical officer, Joanne Waldstreicher, told the Pink Sheet's Sukaina Virji in an interview about how the company went about engaging in initiatives to share its clinical trial data and make drugs available for compassionate use.

Clinical Trials Research & Development

Henri Termeer Dies Aged 71

Biotech mourns the loss of one of its giants.

Commercial Appointments

Could Tecentriq's Bladder Cancer Setback Be A Class Effect?

The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?

Research & Development Cancer
See All
Advertisement
UsernamePublicRestriction

Register